Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Rochester Drug Co-Op Sues Reckitt Over Heroin Treatment

Rochester Drug Co-Operative Inc., a distributor of generic drugs, sued U.K. pharmaceutical maker Reckitt Benckiser Group Plc for allegedly monopolizing the market for heroin treatment.

Reckitt developed a sublingual strip version of its Suboxone anti-addiction drug to replace the tablet form, Rochester Drug said in its lawsuit, filed today in U.S. District Court in Wilmington, Delaware. This prevented competition because pharmacists wouldn’t be allowed to substitute the cheaper generic version, according to Rochester Drug’s lawsuit.

“Reckitt concocted a multifaceted anticompetitive scheme, executed over the course of several years, to maintain and extend its monopoly power,” Rochester Drug claimed in its complaint.

Suboxone is used by heroin addicts to help control the withdrawal symptoms. It costs about $8 a tablet and earned Reckitt about $1 billion in U.S. sales, according to the complaint.

Rochester Drug is seeking class-action, or group, status for the case so it can sue on behalf of itself and others who may have been harmed by Reckitt’s actions.

Dean Mastrojohn, a spokesman for Reckitt Benckiser North America, didn’t immediately return an e-mail seeking comment on the lawsuit.

The case is Rochester Drug Co-Operative Inc. v. Reckitt Benckiser Inc., U.S. District Court, District of Delaware (Wilmington).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.